Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Kaos Capital pushes for board changes at Capricor Therapeutics
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance